Learn about VE303, a potential first-in-class Live Biotherapeutic Product for preventing recurrent Clostridioides difficile ...

Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...

Discover the groundbreaking AI-based platform that designs peptides to target and destroy previously 'undruggable' ...

Glox Therapeutics secures £500K from a £3M fund to develop antibiotics targeting antimicrobial-resistant lung infections in ...

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

Casdozokitug, combined with atezolizumab and bevacizumab, shows durable responses and a 17.2% complete response rate in HCC ...

Learn about the gut-brain connection in mental health and how targeting serotonin in the gut could revolutionise ...

Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Cancer Research UK, Cytovation, and the Norwegian Cancer Society collaborate to advance treatment for adrenocortical ...